Literature DB >> 15379837

Risk of malignancy in diagnosed coeliac disease: a 24-year prospective, population-based, cohort study.

T R Card1, J West, G K T Holmes.   

Abstract

BACKGROUND: There is recent evidence from studies of hospitalized and of undiagnosed patients that the risk of lymphoma for people with coeliac disease may be lower than previously thought. In addition, there have been no precise estimates of small bowel lymphoma risk due to a lack of population data. AIM: To examine these and other malignant risks in a cohort of patients more typical of those seen in routine clinical practice.
METHODS: A prospective cohort study of incident malignancy rates in patients with coeliac disease in southern Derbyshire compared with general population figures.
RESULTS: During 5684 person years of follow-up 31 malignancies (excluding non-melanoma skin cancer) occurred in comparison with 30.30 expected [standardized incidence ratio (SIR) 1.02 (0.69-1.45)]. There were four non-Hodgkin's lymphomas (0.69 expected) SIR 5.81 (1.58-14.86), of which one originated in small bowel (0.02 expected) SIR 40.51 (1.03-225.68). GI malignancy occurred in nine (5.71 expected) SIR 1.58 (0.72-2.99), and breast cancer in three (5.08 expected) SIR 0.59 (0.12-1.73).
CONCLUSIONS: There is no increase in the risk of incident malignancy in this population and the risk of non-Hodgkin's lymphoma in general or of the small bowel is lower than previously found from UK coeliac cohorts.

Entities:  

Mesh:

Year:  2004        PMID: 15379837     DOI: 10.1111/j.1365-2036.2004.02177.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  30 in total

1.  Screening for celiac disease in average-risk and high-risk populations.

Authors:  Saurabh Aggarwal; Benjamin Lebwohl; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

Review 2.  Hematologic manifestations of celiac disease.

Authors:  Thorvardur R Halfdanarson; Mark R Litzow; Joseph A Murray
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

Review 3.  Recent advances in coeliac disease.

Authors:  D A van Heel; J West
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

4.  Malignancy and mortality in a population-based cohort of patients with coeliac disease or "gluten sensitivity".

Authors:  L A Anderson; S A McMillan; R G P Watson; P Monaghan; A T Gavin; C Fox; L J Murray
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 5.  Pediatric and adult celiac disease: similarities and differences.

Authors:  Ujjal Poddar
Journal:  Indian J Gastroenterol       Date:  2013-05-29

Review 6.  Screening for celiac disease in the general population and in high-risk groups.

Authors:  Jonas F Ludvigsson; Timothy R Card; Katri Kaukinen; Julio Bai; Fabiana Zingone; David S Sanders; Joseph A Murray
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

Review 7.  The spectrum of celiac disease: epidemiology, clinical aspects and treatment.

Authors:  Greetje J Tack; Wieke H M Verbeek; Marco W J Schreurs; Chris J J Mulder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-03-09       Impact factor: 46.802

8.  Adherence to biopsy guidelines increases celiac disease diagnosis.

Authors:  Benjamin Lebwohl; Robert C Kapel; Alfred I Neugut; Peter H R Green; Robert M Genta
Journal:  Gastrointest Endosc       Date:  2011-05-20       Impact factor: 9.427

9.  Risk of cutaneous malignant melanoma in patients with celiac disease: a population-based study.

Authors:  Benjamin Lebwohl; Hanna Eriksson; Johan Hansson; Peter H R Green; Jonas F Ludvigsson
Journal:  J Am Acad Dermatol       Date:  2014-05-01       Impact factor: 11.527

10.  Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association.

Authors:  Ying Gao; Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Neil E Caporaso; Ola Landgren
Journal:  Gastroenterology       Date:  2008-09-25       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.